Lamivudine Monotherapy in an HIV-Infected Patient With the M184V Mutation

Abstract

References

Campbell TB , Shulman NS , Johnson SC , et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005;41:236-242.

Catucci M , Venturi G , Romano L , et al. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. J Acquir Immune Defic Syndr. 1999;21: 203-208.

Quan Y , Brenner BG , Oliveira M , Wainberg MA . Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother. 2003;47:747-754.

Merrill DP , Moonis M , Chou TC , Hirsch MS . Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996;173:355-364.

Eron JJ , Benoit SL , Jemsek JJ , et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333: 1662-1669.

Castagna A , Danise A , Menzo S , et al. Lamivudine-monotherapy in HIV-1 infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20: 795-803.

Deeks SG , Wrin T , Liegler T , et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.

van Leeuwen R , Katlama C , Kitchen V , et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-1171.